{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:02:42Z","timestamp":1788303762875,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clnu.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:55:23Z","timestamp":1758765323000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Body mass, linear growth, and body composition before and after the introduction of elexacaftor\/tezacaftor\/ivacaftor among children and adults with cystic fibrosis"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-8703","authenticated-orcid":false,"given":"Karlen","family":"Bader-Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi Uhre","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esben","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bryrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Leo-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Hee Mabuza","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Faurholt-Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavs","family":"Qvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Oturai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majbritt","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Vebert","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Frahm","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bryrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Faurholt-Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esben Herborg","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"H\u00f8jte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majbritt","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Bj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terese","family":"Katzentein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlen","family":"Bader-Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Leo-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Hee","family":"Mabuza Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi Uhre","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Vebert","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Frahm","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavs","family":"Qvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Kristian","family":"R\u00e5ket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen Jimenez","family":"Solem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5\u20136","key":"10.1016\/j.clnu.2025.09.008_bib1","first-page":"393","article-title":"Growth failure in children with cystic fibrosis","volume":"25","author":"Scaparrotta","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.clnu.2025.09.008_bib2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"issue":"9","key":"10.1016\/j.clnu.2025.09.008_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"Bass","year":"2021","journal-title":"Nutrients"},{"issue":"Suppl 1","key":"10.1016\/j.clnu.2025.09.008_bib4","first-page":"S6","article-title":"Nutritional status in the era of highly effective CFTR modulators","volume":"59","author":"Bass","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"10.1016\/j.clnu.2025.09.008_bib5","article-title":"Evolving nutritional needs in cystic fibrosis","volume":"13","author":"Frantzen","year":"2023","journal-title":"Life (Basel)"},{"issue":"5","key":"10.1016\/j.clnu.2025.09.008_bib6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnu.2025.09.008_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.clnu.2025.09.008_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-023-02451-0","article-title":"Heterogeneity of weight gain after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.clnu.2025.09.008_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir Med"},{"issue":"19","key":"10.1016\/j.clnu.2025.09.008_bib10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.clnu.2025.09.008_bib11","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clnu.2025.09.008_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.clnu.2025.09.008_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.clnu.2025.09.008_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged \u2a7e6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clnu.2025.09.008_bib15","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202502-0512OC","article-title":"Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children >\/=6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study","author":"Wainwright","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clnu.2025.09.008_bib16","series-title":"The Canadian cystic fibrosis registry 2022 annual data report","author":"Canada","year":"2022"},{"issue":"4","key":"10.1016\/j.clnu.2025.09.008_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jcf.2024.05.009","article-title":"Improved early growth in Danish children with cystic fibrosis from 2000-2022","volume":"23","author":"Bader-Larsen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.clnu.2025.09.008_bib18","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westholter","year":"2024","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.clnu.2025.09.008_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/nu16193293","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study","volume":"16","author":"Hevilla","year":"2024","journal-title":"Nutrients"},{"issue":"1535","key":"10.1016\/j.clnu.2025.09.008_bib20","article-title":"One-year assessment of body composition in cystic fibrosis patients on elexacaftor-tezacaftor-ivacaftor","volume":"7","author":"Zamponi","year":"2023","journal-title":"Clin Case Rep Int"},{"issue":"5","key":"10.1016\/j.clnu.2025.09.008_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"issue":"12","key":"10.1016\/j.clnu.2025.09.008_bib22","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","article-title":"A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation","volume":"42","author":"Knott-Torcal","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnu.2025.09.008_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2024.112425","article-title":"Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: a follow-up study","volume":"123","author":"Navas-Moreno","year":"2024","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.clnu.2025.09.008_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.clnu.2025.09.008_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27463","article-title":"Growth, body composition, and strength of children with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor (ETI)","volume":"60","author":"Boat","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clnu.2025.09.008_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bone.2017.06.010","article-title":"Body composition by DXA","volume":"104","author":"Shepherd","year":"2018","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.clnu.2025.09.008_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/nu14061216","article-title":"The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity","volume":"14","author":"Bailey","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2025.09.008_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41430-025-01589-y","article-title":"A systematic review of the impact of Elexacaftor\/Tezacaftor\/Ivacaftor on body composition in people with cystic fibrosis","author":"Kinsey","year":"2025","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clnu.2025.09.008_bib29","series-title":"Child growth standards","year":"2025"},{"issue":"1","key":"10.1016\/j.clnu.2025.09.008_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S1368980018002434","article-title":"Prevalence thresholds for wasting, overweight and stunting in children under 5 years","volume":"22","author":"de Onis","year":"2019","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.clnu.2025.09.008_bib31","series-title":"Body Mass Index Among Adults","year":"2025"},{"key":"10.1016\/j.clnu.2025.09.008_bib32","series-title":"_R: a language and environment for statistical computing_","author":"Team","year":"2023"},{"key":"10.1016\/j.clnu.2025.09.008_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jped.2025.05.007","article-title":"Efficacy and safety of using Elexacaftor\/Tezacaftor\/Ivacaftor in the treatment of children with cystic fibrosis: real-world evidence from Brazil","author":"Martins","year":"2025","journal-title":"J Pediatr (Rio J)"},{"issue":"4","key":"10.1016\/j.clnu.2025.09.008_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/apm.13375","article-title":"Close monitoring and early intervention: management principles for cystic fibrosis in Denmark","volume":"132","author":"Qvist","year":"2024","journal-title":"APMIS"},{"issue":"3","key":"10.1016\/j.clnu.2025.09.008_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clnu.2025.09.008_bib36","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"4","key":"10.1016\/j.clnu.2025.09.008_bib37","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MPG.0b013e318156c2db","article-title":"Validation of a nutrition risk screening tool for children and adolescents with cystic fibrosis ages 2-20 years","volume":"46","author":"McDonald","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.clnu.2025.09.008_bib38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jand.2016.01.012","article-title":"Validation of a nutrition screening tool for pediatric patients with cystic fibrosis","volume":"116","author":"Souza Dos Santos Simon","year":"2016","journal-title":"J Acad Nutr Diet"},{"issue":"4","key":"10.1016\/j.clnu.2025.09.008_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.clnu.2025.09.008_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jcf.2021.06.004","article-title":"The association between body composition, leptin levels and glucose dysregulation in youth with cystic fibrosis","volume":"20","author":"Granados","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.clnu.2025.09.008_bib41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcf.2017.02.007","article-title":"Peripheral muscle abnormalities in cystic fibrosis: etiology, clinical implications and response to therapeutic interventions","volume":"16","author":"Gruet","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnu.2025.09.008_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.04.010","article-title":"Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment - a Danish prospective cohort","author":"Philipsen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1284878","key":"10.1016\/j.clnu.2025.09.008_bib43","article-title":"Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor\/tezacaftor\/ivacaftor","volume":"6","author":"Gruber","year":"2024","journal-title":"Front Sports Act Living"},{"issue":"6","key":"10.1016\/j.clnu.2025.09.008_bib44","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3803\/EnM.2021.1274","article-title":"Comparison of two DXA systems, hologic Horizon W and GE lunar Prodigy, for assessing body composition in healthy Korean adults","volume":"36","author":"Park","year":"2021","journal-title":"Endocrinol Metab (Seoul)"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425002560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425002560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:53:35Z","timestamp":1762358015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561425002560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"alternative-id":["S0261561425002560"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2025.09.008","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body mass, linear growth, and body composition before and after the introduction of elexacaftor\/tezacaftor\/ivacaftor among children and adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}